Greetings, and welcome to the American Vanguard First Quarter 2024 Earnings Conference Call and Webcast. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Anthony Young, Director of Investor Relations. Thank you. You may begin. Thank you, Jesse, and welcome everyone to American Vanguard's first quarter 2024 earnings review. Our speakers today will be our Chairman and CEO, Eric Wintemute, and our CFO, David Johnson. Also joining us to answer your questions will be our Chief Operating Officer, Bob Trogele, our Chief Information Officer, Tim Donnelly, and our Chief Transformation Officer, Don Galdoni. Before beginning the presentation, let's take a moment for a cautionary reminder. The company, from time to time, may discuss forward-looking information. Except for the historical information contained in this release, all forward-looking statements are estimates by the company's management and are subject to various risks and uncertainties that may cause results to differ from management's current expectations. Such factors include weather conditions, changes in regulatory policy, and other risks as detailed from time to time in the company's SEC reports and filings. All forward-looking statements, if any, in this release, present the company's judgment as of the date of this release. With that, I will turn the call over to Eric. Thank you, Anthony. Hello, everyone, and welcome to American Vanguard's first quarter 2024 earnings call. We appreciate your continued support and interest. As you'll note from slide 4, I will be covering 4 topics today: our Q1 2024 financial performance, current market conditions, our 2024 outlook, and our transformation efforts. Moving to slide 5, on Q1 performance, we recorded a 35% jump in Adjusted EBITDA during the period. In addition, our operating income rose by 87%. This improvement in operating leverage is evidence that the cost control initiatives that we have started in the second half of 2023 are having their desired effect. As I've mentioned in prior calls, our cross-functional teams remain focused on controlling expenses while maximizing operational efficiency. In that vein, we recorded lower operating expenses as a percent of net sales while increasing sales by 8%. Further, all three of our businesses grew during the quarter. Within our consolidated net sales results, U.S. crop was up 9%, U.S. non-crop, 28%, and international, 2%. Now let's turn to our sales during Q1 as per slide 6. In U.S. crop, we experienced strong results across multiple crops. Sales of our granular soil insecticides rose, which is indicative of continued strong demand from corn growers. Further, we experienced strong sales of our liquid corn soil insecticide Index. Similarly, herbicides rose during the period, due in part to Dacthal, which was not available last year due to supply issues. Also, Thimet sales rose, with demand driven by increased peanut acreage. These increases were partially offset by a drop in soil fumigant sales, as wet conditions in the Northwest truncated the application window. Within U.S. non-crop, our mosquito adulticide sales were up in anticipation of stronger than normal tropical storm activity. Also, our sales of pest strips were up significantly as consumer and technical markets recovered from the prior year. In addition, our ornamental and nursery business, OHP, recorded stronger sales, led by its biorational and pre-emergence product lines. Our international business was up slightly at the top line, led by Mexico, where most product lines grew, and APAC, aided by favorable weather conditions in Australia. Our LatAm business was about even for the quarter, with the addition of sales from our recently acquired business in Ecuador, partially offset by generic pressure in Central America. All told then, all three of our businesses demonstrated improved performance, and on a consolidated basis, we continue to grow. Before moving on to current market conditions and our 2024 outlook and details on transformation, I would like to turn the call over to David for his financial analysis. David? Thank you, Eric. I will begin my comments with a recap of our first quarter 2024 performance, during the course of which I will present important metrics for the period and will close with comments on working capital. As you will see from slide 8, our overall sales for the first three months of 2024 increased by about 8% from $125 million to $135 million for the reasons that Eric has already outlined. It is worth repeating here that all three of our businesses, U.S. crop up 9%, U.S. non-crop up 28%, and international up 2%, grew at the net sales line. Turning to slide 9. While sales were up 8% overall, gross margin dollars improved by 10%, driven by stronger sales of some of our higher margin insecticides and herbicides, and the strong factory performance. Overall, price volume actions, mix of sales, and factory performance resulted in gross margin that improved slightly from 30.8% to 31.4% of sales. As you will see on slide 10, our operating expenses in the first quarter of 2024 edged up to $36.3 million from $35.3 million in the same period of 2023. This increase was driven primarily by our spending of $1.2 million on developing our digital and business transformation plans. We plan to spend more in the next few quarters to invest in the long-term future of our business by implementing initiatives to achieve substantial improvement in business performance. We will see some initial improvements in 2024 that are expected to be largely offset by transformation spending, and then primarily benefiting 2025 earnings and beyond. In addition, we had increases in general and administrative expenses related to foreign exchange, audit costs, long-term and short-term incentive compensation, and investments in initiatives to improve both our information technology systems and our human resources infrastructure. These cost increases were offset by cost control efforts in selling, regulatory, product development, and R&D. With respect to cash flow, as per slide 11, the company has a pronounced annual cycle of building inventory at the start of the calendar year in order to fuel global sales, particularly during the second and third quarters. It is usual for working capital to expand in the first quarter, and Q1 2024 is pretty much in line with the same period of the prior year. We use our revolver debt to fund working capital expansion at the start of the year and pay down as swiftly as possible as the cash cycle completes, usually later in the year. We have been carefully managing the inventory build as we monitor in-industry demand trends. At the end of the quarter, we had $13.7 million in cash, as compared to $19.6 million this time last year. This improvement in reduced amounts of cash held in order to pay down debt is a result of significant effort at the end of the quarter to pull cash back to the corporate center to reduce debt and interest expenses as much as possible. Looking at our statement of operations on slide 12, you will note that our sales grew by 8%, our gross profit increased by 10%, and our operating expenses increased by only 3%. These factors together generated significant improvement in operating leverage, with operating income up 87% over the same period of 2023. Furthermore, the fair value of our equity instrument improved during the quarter. As a result, profit before interest and tax improved by 107%. Our interest rate increased from 6.8% last year to 8.3% this year, primarily related to movements in the Fed rate, but also as a result of the current modifications we have with our bankers. That includes more flexibility on leverage and fixed charge coverage ratios, but adds about 0.5% of interest rate. At the same time, our borrowings are up as a result of our current investment in working capital. As I just mentioned, our business cycle is such that we will normally see working capital and consequently debt increasing during Q1 and Q2, possibly leveling to slightly up in Q3, and then significant reduction in Q4 as the growing cycle for our major markets completes its own annual cycle. Our tax rate is higher this quarter, primarily as a result of the fact that our entities in Brazil made losses in the first quarter of 2024. Because of Brazil's past business performance, U.S. GAAP does not currently permit us to take the benefit on tax expense that would normally be available. As a result of the increased interest expense and the changes in year-over-year tax expense, our net income is down slightly, even though our operating performance and consequently adjusted EBITDA was up significantly. Turning now to working capital on slide 13, you will see our inventory trends on a quarterly basis for the last several quarters. While inventory grew on an absolute basis in Q1 2024, as compared to Q1 2023, you can see that the increase since 12/31/2023 is actually lower than in 2024 than in 2023. Further, at 39% of net sales, our investment in inventory is similar to the level at this time last year, and though we would like to see this balance come down more quickly, it is something we need to manage carefully down, ensuring that we have the right balance of products in inventory to meet customer needs in a timely manner during the 2024 season. During the later part of the year, we plan to move inventory levels down with the intention of reaching a 2024 year-end target of around 34% of net sales... That sums up my detailed comments. On the whole, the first quarter of 2024 showed improvement in comparison to the same period of 2023, in terms of both operating income and Adjusted EBITDA. The company has embarked on an exciting phase of transformation and is managing to invest in a major initiative and still return a profitable result. And as such, I'm quite pleased with the progress we're making in this regard. This initiative will be critically important to the business in the latter part of 2024 and into 2025 and beyond. With that, I turn the call back to Eric. Eric? Thank you, David. As per slide 14, on news of an improving U.S. economy, the Fed seems to have shifted away from making interest rate hikes and is now debating whether to cut or hold those rates. In addition, the U.S. dollar has begun to strengthen over foreign currencies. While helping consumers with purchasing power over foreign-made goods, the strong dollar, when coupled with high grain inventory stocks, has served to suppress commodity prices compared to 2023. Nevertheless, even as current corn and soybean prices at current levels, farming still remains a profitable business. Further, while still observing conservatism in buying crop inputs, our distribution partners have relaxed their stringent de-stocking approach from last year, at least with respect to our portfolio. In short, the farm economy is strong, and we expect stable, albeit more deliberate, buying activity. The same is true of the non-crop market, where we are seeing further normalization of procurement patterns by retail and professional customers. Now let's turn to slide 15 on our 2024 full-year outlook. While market conditions remain stable, there's one factor involving our herbicide, Dacthal, that causes us to adjust our previous full-year targets. In the course of routine registration review, U.S. EPA has expressed concern over potential health issues of this product. Accordingly, out of abundance of caution, the company has voluntarily suspended sales of Dacthal and submitted a significantly narrow product label to the agency that we believe addresses their concerns. We have committed to maintaining that suspension of sales pending EPA's review and potential approval of that new label. The outcome of the agency's review is uncertain at present, but we are factoring the loss of Dacthal sales into our 2024 forecast numbers. Accordingly, our full year 2024 targets are as follows: We expect net sales to increase between 6%-9% as compared to 2023, while Adjusted EBITDA will be within the range of $60 million-$70 million. The midpoint of this range would be a 16%, I'm sorry, a 19% increase over 2023 Adjusted EBITDA. Further, at that midpoint, our stock is currently trading at a discount of nearly 50%, assuming a standard valuation metric of 10x EBITDA. Let me turn next to our transformation initiatives as per slide 16. On the digital slide, we are working with QAD not only to upgrade to their current adaptive global ERP system, but also to standardize our business processes. At the end of this initiative, then all segments will be following the same processes, using the same set of tools, and drawing from one source of truth. This will give senior management a clear, granular view into our business operations and both increase our ability to make real-time decisions and to plan and forecast with greater accuracy. On the structural transformation side, we are moving quickly with what we call Project Accelerator. Working with Kearney's team, over the next 16 weeks, we'll be doing deep-level analysis in several sub-initiatives in parallel. Within the commercial realm, we will focus on our sales and marketing strategy, pricing, and product mix. Within operation, we will do deep dives into material sourcing, logistics, and manufacturing productivity. Within G&A, we will select and refine an organization design that best supports our future business plan, as well as ensure that these many efforts are managed through a properly resourced transformation office. This broad initiative will generate EBITDA benefits through a range of results, including reduced costs, improved efficiencies, emphasis on higher-margin products, and better-defined roles and responsibilities. As I'd stated in our last call, we are confident that we will gain at least $15 million of annualized adjusted EBITDA by 2026 through this investment. In closing, during the quarter, we navigated our business through complex markets while improving operating efficiencies and growing sales. Further, the 2024 market conditions are stable and I would argue, stronger than 2023. These conditions will serve to generate demand for our products and enable us to improve our inventory and working capital positions. In addition, having begun transformation initiatives in earnest, we are poised to generate even greater operating leverage. In short, we see promising opportunities for growth and are taking strong measures to ensure that we are positioned to capitalize upon them. So with that, I'll turn that back to you, Jesse. Thank you. ... Thank you. Ladies and gentlemen, we will now be conducting our question and answer session. If you would like to ask a question, please press star one on your telephone keypad. The confirmation tone will indicate that your line is in the question queue. You may press star two if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. Our first question is coming from the line of Scott Fortune with Roth MKM. Please proceed with your questions. Yeah, good afternoon, and thanks for the questions. Just want to follow up regarding transformation strategy. Nice to see that that's starting to be implemented here. It looks like that will really come through for most of the year. But I heard you say in your comments that any cost savings for 2024 here will be offset by some of the expenses to that. So kind of, really kind of factoring in more of a 2025 to expect that fifteen million in efficiencies, 25, 26 going forward here. Just want clarification on that from the operations standpoint. Yeah, Scott, that's true. So we do have costs to implement and go through this deep dive that we're going through on implementation right now. You know, we hope to have... We'll have some benefit certainly this year, but as I said, we're projecting that it'll overshadow the amount of money, the transformation. But as we go into 2025, most of the heavy lifting will be done, and we'll start seeing getting that $15 million of improved actual EBITDA. Got it. That's helpful. So, and then just following up on your outlook, obviously bringing it down to the 6%-9% from the 8%-12%, that sales side of it. Just kind of step us through, you know, Dacthal was just getting back on the market, from that standpoint, but kind of, the size of that from a, from a kind of revenue standpoint, that's driving that down a little bit. And are there other factors in that, that sales of 6%-9% outside of Dacthal? And then just any color for, for timing from a historical standpoint, kind of as you reregister this through the EPA. I know it's, this is kind of unknown, but, your sense of timing for Dacthal coming back on potentially. So we submitted the revised label this week. It is a fairly restricted label. We expect the EPA to respond fairly quickly. We've been in strong negotiations and discussions with the EPA now for well over a year, and we think we've kind of reached where we're going to be. And then we discussed pathways of additional information and data that would potentially let us get back at least some of the market that we're not gonna have, certainly in the short term. So the timing of that, you know, some pieces may be relatively quick, but others could be in that 1-3-year timeline, depending on the scope of the studies and then the timing for review. As far as scope, this is about a $15 million product. And we had about a third of that in the first quarter. And so what we've done is we've just made the assumption we're not gonna sell anything more for the balance of the year, and we'll factor that. We'll have a much clearer picture of what 2025 is gonna look like, soon, certainly before we come up with 2025 numbers. And if anything were to change for 2024, we'd certainly adjust it. But at this point, we're not anticipating anything material here in the balance of the year. Got it. As far as- Just a little follow-up on that. Sure. As far as, you know, coming out of the registration process, does that position is even stronger to kind of be a bigger market for you? Or how do you look at that once you get through the process here for the competition and the opportunity for Dacthal? Well, Dacthal was growing nicely for us. It's a very, very niche herbicide, kind of for cole crops and onions. I don't think we see going back into the onion market, but the cole crops. And so, we don't have any assurance that we're gonna get back, you know, any significant amount of that, but we really have to kind of wait and see. Again, this has been a long process we've been in discussion with the EPA, had a very good call this week, but we're waiting to hear back from them, their assessment of what we just submitted. Great. And then one last one for me. You know, any updates on kind of... I know the growth kind of products for you, especially the Green Solutions. We've seen a lot of generic pressure from China in that space, especially impacting Latin America. But the growth that you've seen for this year, expecting 2024, can you kind of kind of highlight the Green Solutions side and the ongoing product adoption from your standpoint? Yeah. So Green Solutions were up fourteen percent this quarter. And most of the growth, I mean, most of the areas had growth. And so that seems to be going well. We have additional opportunities for product expansion as we continue to have companies coming to us and saying, "Hey, with your market access, would you kind of distribute this product and that product?" A number of companies there. We did sign up on a, with Precision Plant, a protein called Harpin for the Chinese market. Not sure how big that'll be, but this is a product that's been around for quite a while. Monsanto had it at one time. But yeah, we see nice growth in that segment as adoption for green products continues to build. So that's kind of the piece on green solutions. Appreciate it. Thanks for all the color, and I'll, I'll jump back in the queue. Thank you. Our next question is coming from the line of Chris Kapsch with Loop Capital Markets. Please proceed with your question. Yeah, good afternoon. I have a couple. Just as a follow-up on the Dacthal discussion, Eric, if I remember correctly, was this the product that you had you mentioned you've been in discussions with the agency for over a year. If I remember correctly, that also manifested in disruption to your to your sourcing the AI for this particular product. And I thought that the outcome of that was that you, you know, came to a resolution, so it's a little surprising to hear this cautious stance and reregistration now. I'm just wondering, you know, what are the risks associated with, you know, getting this to a favorable outcome, and how are you managing that? Yeah. So, the two different issues. One was supply, and we didn't have supply for a year. And so that we have resolved, and we have actually two supply sources. So the supply side was certainly taken care of. On the reregistration process, had different path with the EPA, and we're not necessarily in agreement on their assessment. But rather than push that further with them, we went as far as we think we can go for right now, and we believe we've submitted a revised label that they should accept. But that will be certainly a reduction of the market that we've had. So as far as, yeah, the timing is kind of, as I anticipated, we've got different stages of pieces that we would like to reinstate. And first piece, you know, as I mentioned, we think will be relatively short. The next two kind of run between one and two years, and then maybe between two and three. And not sure that we're gonna wind up doing all of it. We'll assess the market and, as we get further information from EPA. Got it. And the cost associated with this, these sorts of studies and reregistrations, is that just sort of normal course of business and factored into your R&D spend, your normal R&D spend? Right. That's correct. Got it. And then, just curious about this year's, you know, sort of the mood of the growers and the trends in the, you know, in the Midwest. And we came off of what was described related to another company I follow as the most mild winter in, like, 25 years. And so sometimes when that happens, there's, you know, the infestation of the insects is greater. So I'm curious if you-- there's any evidence that was the case for corn rootworm pressure this season? Are you seeing any indications that you could have an uptrend in demand for your soil applied insecticides? I'll let Bob add some color, but I'll just say I'm talking with my people. Yeah, there are wet conditions, particularly in upper regions. So planting at this point is maybe in the 50% range with the South there, but there's large parts of the corn and soybean market that have not been planted yet. So it is an extended period. But Bob, your color? Yeah, I would say, Chris, the mood has been, you know, very cautious by the growers in the Midwest and the U.S. I think there's been this past week a little bit of a pickup in the July corn and soybean pricing, which, you know, people are locking into that and averaging out better if they're doing, you know, forward pricing and contracting. So the mood's picked up, so I think there's more optimism out there. But, you know, you do have pockets right now where people were planting. Someone told me this morning, a grower told me it was, like, April sixteenth, he had about 90% of his planting done, and since then, he hasn't been able to get back in the field because it's been wet. So he's got another 10% to go. That's a long, that's a long window of not stop and go. So there's a little bit of that, but that's, you know, normal for the ag markets. You know, weather is weather. Yeah. With regard to the corn rootworm pressure, so Aztec, and to some degree, Counter and Force, are primarily used in that heavier pressure corn rootworm area. We haven't really participated in the kind of mild to mid corn rootworm pressure. But we have a new product that we put out a couple of years ago, but we just haven't had enough material. We make it internally, but demand has gone faster than we can, than we've been able to produce. But we had good production and sales in the first quarter, up until, I think we were up until April seventeenth, eighteenth, or whatever, we were selling product. And we're building inventory now for kind of the fourth quarter, because we do—we did have stronger demand than what we had supply, but we're thinking we can kind of dramatically increase. And this is again, it's a liquid material, so it kind of competes with bifenthrin in that market. And so that's an upside for us going forward. Much more acreage covered or treated for mild to medium Corn rootworm pressure than heavy pressure. That's helpful. And then last question. So your, your herbicide Impact is often used sort of to complement some of the workhorse, broad-spectrum herbicides, and just curious, like, you know, given what had happened with the global supply chain and the, the supply tightness with, with glyphosate globally and the spike in those prices and, and, you know, sort of outsized demand for alternative herbicides. I'm curious how that's played out now that sort of everything's kind of normalized in terms of pricing and availability and, and some of the, you know, the, the, the row crop herbicides. Thanks. And then, then how that affects your, your Impact sales and, and how does that play out in your, in your guidance and expectations this year? Thank you. Yeah. I mean, I think you recall that herbicides were kind of a glut, that prices were high in 2022 and came down in 2023 and there was high inventory and high price out there. Seems to have improved, but if I look looking at the larger peers, first quarter was not good for them. So I think there's probably still some hangover into that herbicide market. We don't have the kind of large bulk scale, although we do have Impact with glufosinate as a product. And so, yeah, again, Impact has been more a tank mix partner than, you know, a main horse. But it looks improved versus last year. Is there any way to quantify that, the improvement? Like, what's factored into your outlook on that particular product? And then I'll leave it at that. Thanks. Yeah, we were just about even to last year. I think we had good fourth quarter sales versus the prior year. It looks like we're about even in the first quarter. And then, second quarter looks considerably stronger than last year's second quarter. Thank you. Thank you. As a reminder, ladies and gentlemen, if you would like to ask a question at this time, please press star one on your telephone keypad. Our next question comes from the line of Andrew Lester with Arla Capital. Please proceed with your question. Hi, thank you for taking the question. If I'm reading it correctly, and forgive me if I if I'm off by this, 18 months ago, or 24 months ago, you sounded very optimistic. You laid out some exciting timelines and information, and even, you know, in the last year or so, again, you sounded very clear on ways to enhance value, do board refreshes. There were all sorts of things that we were pointing to as milestones to lead to significantly better results. When I listen to you today, you sound very tentative, equivocal, and really uncertain, and looking for really a more significant improvement without quantification for, like, a year from now. Is that a fair read? Have you become much more cautious about your prospects? Well, I would say that we are pointing towards improvement through the transformation process, but that has an expense of transforming. Now, it's one-time expense, but yeah, as we've mentioned before, that we've grown through acquisitions of companies from since 2017, and we did not get the benefit of incorporating those the way we wanted to, and hampered certainly during COVID. But the process now is that we put underway is to get all the systems on the same page, so that we can do better management and where we deploy working capital and improve the quality. And as I said, our target here, I think we're maybe 11.5% of EBITDA to sales. What we're looking through this transformation process is to improve that EBITDA margin to 15%. But if I look at things, just a follow-up, on a sort of more mercenary basis, as a shareholder, I'm probably down over 40% in the past year. How do you think, or when do you expect things to translate into better equity performance? ... Well, I think we're up a little over 14% so far this year. As we mentioned last year, we were hit with two supply issues that really hurt us. One was our biggest insecticide, and the second was the supply of Dacthal that we mentioned. So we've improved the sourcing on both of those. We have ample material of Aztec going forward. And so that was really a hit to fourth quarter of 2022 and certainly to 2023, and we were unable to meet demand. Supply-wise, we're in a different position, and we're back to moving Aztec and now Index and Force and Smart Choice back up into the corn market. So, I guess—I mean, I look at what, where our peers have been discussing. They forecasted downsides in Q1, and that turned out to be the case. We did have improvements in Q1. So, yeah, we've made the forecast based upon the best that we can see at this point. Okay. Thank you for your time. Thank you. Once again, ladies and gentlemen, if you would like to ask a question at this time, please press star one on your telephone keypad. Please hold while we poll for additional questions. Ladies and gentlemen, it appears we have no additional questions at this time, so I'd like to turn the floor back over to Mr. Wintemute for any additional closing remarks. Okay. So thank you all for listening in today. Provide updates as we have them, but I guess the next scheduled time would be our shareholders' meeting, which I believe is June sixth or seventh? Sixth, yeah. Okay. Thank you, and have a good evening. Bye. Ladies and gentlemen, this does conclude today's teleconference. We thank you for your participation, and you may disconnect your lines at this time.